<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To report a rare case of combined <z:e sem="disease" ids="C0543698" disease_type="Disease or Syndrome" abbrv="">hypersensitivity syndrome</z:e> and pure red cell <z:mpath ids='MPATH_58'>aplasia</z:mpath> (PRCA) following <z:chebi fb="0" ids="40279">allopurinol</z:chebi> therapy </plain></SENT>
<SENT sid="1" pm="."><plain>CASE SUMMARY: A 43-year-old woman with underlying mesangioproliferative <z:hpo ids='HP_0000099'>glomerulonephritis</z:hpo> developed <z:hpo ids='HP_0001945'>fever</z:hpo>, generalized morbilliform <z:e sem="disease" ids="C0015230" disease_type="Disease or Syndrome" abbrv="">rash</z:e>, <z:hpo ids='HP_0001974'>leukocytosis</z:hpo> with marked <z:hpo ids='HP_0001880'>eosinophilia</z:hpo>, and hepatic dysfunction 3 weeks after starting <z:chebi fb="0" ids="40279">allopurinol</z:chebi> therapy (300 mg/day for 3 days followed by 200 mg/day) for <z:hpo ids='HP_0002149'>hyperuricemia</z:hpo> and <z:hpo ids='HP_0001369'>arthritis</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The clinical findings were judged to be a probable drug reaction according to the Naranjo probability scale </plain></SENT>
<SENT sid="3" pm="."><plain>The <z:e sem="disease" ids="C1168290" disease_type="Disease or Syndrome" abbrv="">drug-induced hypersensitivity syndrome</z:e> (DHS) resolved after withdrawal of <z:chebi fb="0" ids="40279">allopurinol</z:chebi> and initiation of systemic <z:chebi fb="0" ids="50858">corticosteroid</z:chebi> therapy </plain></SENT>
<SENT sid="4" pm="."><plain>However, there was progressive worsening of <z:hpo ids='HP_0001903'>anemia</z:hpo> with <z:hpo ids='HP_0001896'>reticulocytopenia</z:hpo>; PRCA was suspected </plain></SENT>
<SENT sid="5" pm="."><plain>PRCA was judged to be a possible drug reaction according to the Naranjo probability scale </plain></SENT>
<SENT sid="6" pm="."><plain>The patient refused blood transfusion and bone marrow biopsy </plain></SENT>
<SENT sid="7" pm="."><plain>Recombinant human erythropoietin was initiated in addition to <z:chebi fb="2" ids="8378">prednisolone</z:chebi> 15 mg daily </plain></SENT>
<SENT sid="8" pm="."><plain>Eleven days later (approximately 7 wk after <z:chebi fb="0" ids="40279">allopurinol</z:chebi> withdrawal), both the <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> level and reticulocyte count began to rise </plain></SENT>
<SENT sid="9" pm="."><plain>The patient consented to a bone marrow study at that time, which confirmed the presence of <z:mpath ids='MPATH_589'>dysplasia</z:mpath> involving only the erythroid lineage </plain></SENT>
<SENT sid="10" pm="."><plain>DISCUSSION: <z:chebi fb="0" ids="40279">Allopurinol</z:chebi> may induce DHS, <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, and, in rare instances, PRCA </plain></SENT>
<SENT sid="11" pm="."><plain>We report the first case of PRCA concurrent with <z:chebi fb="0" ids="40279">allopurinol</z:chebi>-induced DHS in a patient with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0022658" disease_type="Disease or Syndrome" abbrv="">kidney disease</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>Discontinuation of <z:chebi fb="0" ids="40279">allopurinol</z:chebi> is the first step in the treatment of such cases </plain></SENT>
<SENT sid="13" pm="."><plain>The slow recovery of PRCA might be partly attributed to her underlying <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0022658" disease_type="Disease or Syndrome" abbrv="">kidney disease</z:e> </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSIONS: To minimize serious DHS, proper indications for treatment and dosage adjustment should be closely observed when starting <z:chebi fb="0" ids="40279">allopurinol</z:chebi> therapy in patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0022658" disease_type="Disease or Syndrome" abbrv="">kidney disease</z:e> </plain></SENT>
</text></document>